دورية أكاديمية
أعرض في EDS

Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).

التفاصيل البيبلوغرافية
العنوان: Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).
المؤلفون: Zeng L; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Perin J; Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Gross AL; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Shade D; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Lanctôt KL; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Lerner AJ; University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA., Mintzer JE; Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, South Carolina, USA., Brawman-Mintzer O; Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, South Carolina, USA., Padala PR; Central Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., van Dyck CH; Yale School of Medicine, New Haven, Connecticut, USA., Porsteinsson AP; University of Rochester School of Medicine and Dentistry, Rochester, New York, USA., Craft S; Wake Forest University, Winston-Salem, North Carolina, USA., Levey A; Emory Goizueta Alzheimer's Disease Research Center, Atlanta, Georgia, USA., Herrmann N; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada., Rosenberg PB; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
المصدر: International journal of geriatric psychiatry [Int J Geriatr Psychiatry] 2024 Jun; Vol. 39 (6), pp. e6108.
نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: John Wiley Country of Publication: England NLM ID: 8710629 Publication Model: Print Cited Medium: Internet ISSN: 1099-1166 (Electronic) Linking ISSN: 08856230 NLM ISO Abbreviation: Int J Geriatr Psychiatry Subsets: MEDLINE
أسماء مطبوعة: Publication: Chichester : John Wiley
Original Publication: Chichester, Sussex, England ; [New York] : Wiley, c1986-
مواضيع طبية MeSH: Alzheimer Disease*/drug therapy , Methylphenidate*/therapeutic use , Methylphenidate*/adverse effects , Apathy*/drug effects , Central Nervous System Stimulants*/therapeutic use , Central Nervous System Stimulants*/adverse effects , Weight Loss*/drug effects , Accidental Falls*/statistics & numerical data, Humans ; Female ; Male ; Aged ; Aged, 80 and over ; Double-Blind Method ; Sleep Initiation and Maintenance Disorders/chemically induced ; Sleep Initiation and Maintenance Disorders/drug therapy
مستخلص: Objectives: To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia.
Methods: The Apathy in Dementia Methylphenidate Trial 2 (ADMET2) trial was a multicenter randomized, placebo-controlled trial of MPH to treat apathy in individuals with apathy and AD. Participants in ADMET2 had vital signs and weight measured at monthly visits through 6 months. AEs, including insomnia, falls, and cardiovascular events, were reported at every visit by participants and families using a symptom checklist.
Results: The study included 98 participants in the MPH group and 101 in the placebo group. Participants in the MPH group experienced greater weight loss on average than the placebo through the 6-month follow-up, with a difference in change between MPH and placebo of 2.8 lb (95% confidence interval, CI: 0.7, 4.9 lb). No treatment group differences in change during the trial were found in systolic and diastolic blood pressure. More participants in the MPH group reported falls during the follow-up, 10 versus 6 in MPH and placebo groups, respectively. No differences in post-baseline insomnia were observed between the treatment groups. No participants reported instances of myocardial infarction, congestive heart failure, arrhythmia, stroke, or cardiomyopathy throughout the study period.
Conclusions: MPH use in AD patients for treating apathy is relatively safe, particularly notable given the many medical comorbidities in this population. There was a statistically significant but modest weight loss associated with MPH use, and clinicians are thus advised to monitor weight during MPH treatment.
(© 2024 John Wiley & Sons Ltd.)
References: J Clin Psychiatry. 2007 Jan;68(1):93-101. (PMID: 17284136)
Int J Environ Res Public Health. 2021 Jun 11;18(12):. (PMID: 34207955)
Alzheimers Dement. 2021 Dec;17(12):1892-1904. (PMID: 33949763)
Int J Geriatr Psychiatry. 2017 Mar;32(3):306-315. (PMID: 27017917)
JAMA Netw Open. 2021 Oct 1;4(10):e2130795. (PMID: 34694389)
Int J Obes (Lond). 2009 Mar;33(3):326-34. (PMID: 19223848)
J Clin Psychiatry. 2003 Dec;64(12):1410-4. (PMID: 14728100)
J Atten Disord. 2011 Jan;15(1):36-45. (PMID: 20071637)
J Clin Psychiatry. 2013 Aug;74(8):810-6. (PMID: 24021498)
J Clin Psychiatry. 2007 Feb;68(2):268-77. (PMID: 17335326)
Biol Psychiatry. 2006 May 1;59(9):829-35. (PMID: 16373066)
Int J Geriatr Psychiatry. 2008 Feb;23(2):170-7. (PMID: 17607801)
Am J Psychiatry. 2018 Feb 1;175(2):159-168. (PMID: 28945120)
JAMA Neurol. 2021 Nov 1;78(11):1324-1332. (PMID: 34570180)
Am J Psychiatry. 2015 Jun;172(6):561-9. (PMID: 25677354)
Int J Geriatr Psychiatry. 2006 Oct;21(10):972-6. (PMID: 16955429)
Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):214-21. (PMID: 12611751)
BMC Psychiatry. 2013 Sep 27;13:237. (PMID: 24074240)
Am J Geriatr Psychiatry. 2006 Feb;14(2):181-5. (PMID: 16473984)
Biometrics. 1997 Sep;53(3):983-97. (PMID: 9333350)
Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. (PMID: 21042924)
معلومات مُعتمدة: U54 AG065187 United States AG NIA NIH HHS; P30 AG066507 United States AG NIA NIH HHS; P30 AG066511 United States AG NIA NIH HHS; U01 AG061357 United States AG NIA NIH HHS; R01 AG046543 United States AG NIA NIH HHS
فهرسة مساهمة: Keywords: Alzheimer's disease; adverse events; apathy; methylphenidate; weight loss
المشرفين على المادة: 207ZZ9QZ49 (Methylphenidate)
0 (Central Nervous System Stimulants)
تواريخ الأحداث: Date Created: 20240610 Date Completed: 20240610 Latest Revision: 20240725
رمز التحديث: 20240726
مُعرف محوري في PubMed: PMC11265565
DOI: 10.1002/gps.6108
PMID: 38858522
قاعدة البيانات: MEDLINE
الوصف
تدمد:1099-1166
DOI:10.1002/gps.6108